Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial

References

• Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48:1532–1542.
   PubMed Web of Science ®Google Scholar
• Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. Cancer Res. 2015;75:4884–4894.
   PubMed Web of Science ®Google Scholar
• Brat DJ, Verhaak RG, Aldape KD, et al. Cancer genome atlas research network. comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–2498.
   PubMed Web of Science ®Google Scholar
• Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018;44:139–150.
   PubMed Web of Science ®Google Scholar
• Van der Vlis TAMB, Hoeben A, Beckervordersandforth JC, et al. Impact of the revised WHO classification of diffuse low-grade glioma on clinical decision making: a case report. Surg Neurol Int. 2017;8:223.
   PubMedGoogle Scholar
• Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374:1344–1355.
   PubMed Web of Science ®Google Scholar
• Edelstein K, Richard NM, Bernstein LJ. Neurocognitive impact of cranial radiation in adults with cancer: an update of recent findings. Curr Opin Support Palliat Care. 2016;11:1–37.
   Web of Science ®Google Scholar
• Chakraborty S, Patil VM, Babu S, et al. Locoregional recurrences after post-operative volumetric modulated arc radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting: experience and lessons learned. BJR. 2015;88:20140795.
   PubMed Web of Science ®Google Scholar
• Gondi V, Pugh SL, Tomé WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase 2 multi-institutional trial. JCO. 2014;32:3810–3816.
   PubMed Web of Science ®Google Scholar
• Tian X, Liu K, Hou Y, et al. The evolution of proton beam therapy: current and future status. Mol Clin Oncol. 2017;8:15–21.
   PubMed Web of Science ®Google Scholar
• Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status. Jpn J Clin Oncol. 2016;46:885–892.
   PubMed Web of Science ®Google Scholar
• Austin AM, Douglass MJJ, Nguyen GT, et al. A radiobiological Markov simulation tool for aiding decision making in proton therapy referral. Phys Med. 2017;44:72–82.
   PubMed Web of Science ®Google Scholar
• Lühr A, von Neubeck C, Krause M, et al. Relative biological effectiveness in proton beam therapy – current knowledge and future challenges. Clin Transl Radiat Oncol. 2018;9:35–41.
   PubMed Web of Science ®Google Scholar
• Eekers DB, Roelofs E, Jelen U, et al. Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiother Oncol. 2016;121:387–394.
   PubMed Web of Science ®Google Scholar
• Van der Laan HP, van de Water TA, van Herpt HE, et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: a planning comparative study. Acta Oncol. 2013;52:561–569.
   PubMed Web of Science ®Google Scholar
• Roelofs E, Engelsman M, Rasch C, et al. ROCOCO Consortium. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol. 2012;7:165–176.
   PubMed Web of Science ®Google Scholar
• Eekers DBP, Roelofs E, Mesías C, et al. Data from: intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial. Cancer Data. 2017. DOI:10.17195/candat.2018.05.1
   Google Scholar
• Eekers DBP, in ’t Ven L, Roelofs E, et al. The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology. Radiother Oncol. 2018. DOI:10.1016/j.radonc.2017.12.013
   Web of Science ®Google Scholar
• Roelofs E, Persoon L, Qamhiyeh S, et al. Design of and technical challenges involved in a framework for multicentric radiotherapy treatment planning studies. Radiother Oncol. 2010;97:567–571.
   PubMed Web of Science ®Google Scholar
• ICRU. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83. J ICRU. 2010;10:1–106.
   Google Scholar
• Van't Riet A, Mak AC, Moerland MA, et al. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. Int J Radiat Oncol Biol Phys. 1997;37:731–736.
   PubMed Web of Science ®Google Scholar
• Koca T, Basaran H, Sezen D, et al. Comparison of linear accelerator and helical tomotherapy plans for glioblastoma multiforme patients. Asian Pac J Cancer Prev. 2014;15:7811–7816.
   PubMedGoogle Scholar
• Cao D, Holmes TW, Afghan MK, et al. Comparison of plan quality provided by intensity-modulated arc therapy and helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;69:240–250.
   PubMed Web of Science ®Google Scholar
• Skórska M, Piotrowski T, Kaźmierska J, et al. A dosimetric comparison of IMRT versus helical tomotherapy for brain tumors. Phys Med. 2014;30:497–502.
   PubMed Web of Science ®Google Scholar
• Harrabi SB, Bougatf N, Mohr A, et al. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther Onkol. 2016;192:759–769.
   PubMed Web of Science ®Google Scholar
• Dennis ER, Bussiere MR, Niemierko A, et al. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy. Technol Cancer Res Treat. 2013;12:1–9.
   PubMed Web of Science ®Google Scholar
• Beltran C, Roca M, Merchant TE. On the benefits and risks of proton therapy in pediatric raniopharyngioma. Int J Radiat Oncol Biol Phys. 2012;82:e281–e287.
   PubMedGoogle Scholar
• Schneider U, Lomax A, Pemler P, et al. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:892–897.
   PubMed Web of Science ®Google Scholar
• Sherman JC, Colvin MK, Mancuso SM, et al. Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neurooncol. 2016;126:157–164.
   PubMed Web of Science ®Google Scholar
• Shih HA, Sherman JC, Nachtigall LB, et al. Proton therapy for low-grade gliomas: results from a prospective trial. Cancer. 2015;121:1712–1719.
   PubMed Web of Science ®Google Scholar
• Brown PD, Buckner JC, Uhm JH, et al. The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro-oncology. 2003;5:161–167.
   PubMed Web of Science ®Google Scholar
• Kraan AC, van de Water S, Teguh DN, et al. Dose uncertainties in IMPT for oropharyngeal cancer in the presence of anatomical, range, and setup errors. Int J Radiat Oncol Biol Phys. 2013;87:888–896.
   PubMed Web of Science ®Google Scholar
• Rana S, Zheng Y. Impact of grid size on uniform scanning and IMPT plans in XiO treatment planning system for brain cancer. J Appl Clin Med Phys. 2015;16:447–456.
   PubMed Web of Science ®Google Scholar
• Liu W, Patel SH, Shen JJ, et al. Robustness quantification methods comparison in volumetric modulated arc therapy to treat head and neck cancer. Pract Radiat Oncol. 2016;6:e269–e275.
   PubMed Web of Science ®Google Scholar
• Combs SE. Does proton therapy have a future in CNS tumors? Curr Treat Options Neurol. 2017;19:12.
   PubMed Web of Science ®Google Scholar
• Klein M. Treatment options and neurocognitive outcome in patients with diffuse low-grade glioma. J Neurosurg Sci. 2015;59:383–392.
   PubMed Web of Science ®Google Scholar
• Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–818.
   PubMed Web of Science ®Google Scholar
• Armstrong CL, Hunter JV, Ledakis GE, et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology. 2002;59:40–48.
   PubMed Web of Science ®Google Scholar
• Ravn S, Holmberg M, Sørensen P, et al. Differences in supratentorial white matter diffusion after radiotherapy – new biomarker of normal brain tissue damage? Acta Oncol. 2013;52:1314–1319.
   PubMed Web of Science ®Google Scholar
• Olson JD, Riedel E, DeAngelis L. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54:1442–1448.
   PubMed Web of Science ®Google Scholar
• Peiffer AM, Leyrer CM, Greene-Schloesser DM, et al. Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline. Neurology. 2013;80:747–753.
   PubMed Web of Science ®Google Scholar
• Hauswald H, Rieken S, Ecker S, et al. First experiences in treatment of low-grade glioma grade I and II with proton therapy. Radiat Oncol. 2012;7:189.
   PubMed Web of Science ®Google Scholar
• Wilkinson B, Morgan H, Gondi V, et al. Low levels of acute toxicity associated with proton therapy for low-grade glioma: a Proton Collaborative Group study. Int J Radiat Oncol Biol Phys. 2016;96:E135.
   PubMed Web of Science ®Google Scholar
• Wertz H, Jäkel O. Influence of iodine contrast agent on the range of ion beams for radiotherapy. Med Phys. 2004;31:767–773.
   PubMed Web of Science ®Google Scholar
• Gondi V, Hermann BP, Mehta MP, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85:348–354.
   PubMed Web of Science ®Google Scholar
• Eekers DBP, in 't Ven L, Deprez S, et al. The posterior cerebellum, a new organ at risk? Clin Transl Radiat Oncol. 2018;8:22–26.
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Lambin P, De Ruysscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–273.
   PubMed Web of Science ®Google Scholar
• Lambrecht M, Eekers DBP, Alapetite C, et al. Radiation dose constraints for organs at risk in neuro-oncology. Radiother Oncol. 2018. DOI:10.1016/j.radonc.2018.05.001
   Web of Science ®Google Scholar